Core Viewpoint - The company has approved the unlocking of 3.354 million shares of restricted stock for 67 eligible incentive recipients, which represents 0.45% of the total share capital of 741.609425 million shares, with the listing date set for November 21, 2025 [2][13]. Group 1: Stock Incentive Plan Details - The board of directors confirmed that the conditions for the third unlocking period of the restricted stock incentive plan have been met, allowing for the release of shares [3][10]. - The initial grant of restricted stock was completed on November 21, 2022, and the third unlocking period will end on November 20, 2025 [9][10]. - The total number of restricted shares granted in the initial plan was 11.3976 million shares at a price of 5.66 yuan per share, with 70 recipients [5][11]. Group 2: Approval Process and Compliance - The company followed all necessary approval procedures for the stock incentive plan, including independent opinions from directors and legal advice from Beijing Deheng Law Firm [4][5]. - The company conducted a self-examination regarding insider trading related to the stock incentive plan and reported the findings [5]. Group 3: Adjustments and Changes - The repurchase price for the restricted stock was adjusted from 5.66 yuan to 5.56 yuan due to the completion of the 2022 annual equity distribution plan [11][12]. - The company has also approved the repurchase and cancellation of restricted stocks for recipients who have left the company [12].
桂林莱茵生物科技股份有限公司 关于2022年限制性股票激励计划首次授予部分第三个解除限售期 解除限售股份上市流通的提示性公告